NASDAQ:BCLI
Brainstorm Cell Therapeutics Inc. Stock News
$0.342
-0.0106 (-3.00%)
At Close: Jul 03, 2024
BrainStorm Cell Therapeutics to Provide Corporate Mid-Year Update on NurOwn Program
06:00am, Monday, 01'st Jul 2024
A conference call and webcast will be held Monday, July 8, at 8:00 a.m. Eastern Time NEW YORK , July 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of ad
BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering
09:15am, Thursday, 27'th Jun 2024
NEW YORK , June 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) (the "Company"), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today ann
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
08:00am, Wednesday, 26'th Jun 2024
NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has r
BrainStorm Cell Therapeutics Announces Appointment of Haro Hartounian Ph.D. as Chief Operating Officer
06:00am, Thursday, 20'th Jun 2024
Appointment Completes Executive Readiness for Registrational Phase 3b ALS Study Launch NEW YORK , June 20, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer
FROM ACF EQUITY RESEARCH HEALTHCARE TEAM NASDAQ: BCLI READ ACF EQUITY RESEARCH'S INITIATION NOTE HERE READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEG
The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical approval
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
04:30pm, Tuesday, 14'th May 2024
Company received written agreement from the U.S. FDA under a Special Protocol Assessment (SPA) on the design for a Phase 3b trial of NurOwn® Conference call planned for later this quarter to provid
BrainStorm Cell Therapeutics Announces Management Changes as Company Plans Registrational Phase 3b Trial of NurOwn
06:30pm, Tuesday, 16'th Apr 2024
Bob Dagher, MD, Promoted to Chief Medical Officer Dr. Stacy Lindborg Stepping Down as Co-CEO and Transitioning to Board of Directors NEW YORK , April 16, 2024 /PRNewswire/ -- BrainStorm Cell Therap
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule
06:00am, Thursday, 11'th Apr 2024
NEW YORK , April 11, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI, "the Company"), a leading developer of cellular therapies for neurodegenerative diseases, today announced tha
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS
06:00am, Wednesday, 10'th Apr 2024
NurOwn treatment resulted in a positive impact on important CSF biomarkers relevant to ALS compared to placebo.Significant changes in multiple ALS disease pathways support NurOwn's mechanism of action
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
06:00am, Tuesday, 09'th Apr 2024
Conference call and webcast at 8:00 a.m. Eastern Time today NEW YORK , April 9, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeut
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
06:00am, Monday, 08'th Apr 2024
A conference call and webcast will be held Tomorrow, April 9, at 8:00 a.m. Eastern Time NEW YORK , April 8, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer o
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update
08:05am, Monday, 01'st Apr 2024
Conference call planned for early April 2024 to provide update on NurOwn program NEW YORK , April 1, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adu
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference
06:30am, Tuesday, 27'th Feb 2024
Planned Phase 3b trial Designed to Confirm Efficacy and Safety of NurOwn in mild-to-moderate ALS patients NEW YORK , Feb. 27, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI),
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS
06:00am, Friday, 23'rd Feb 2024
NEW YORK , Feb. 23, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that it h